Moderna’s journey through the pandemic, its stock fluctuations, updated
COVID-19 vaccine, and other vaccine developments are being closely monitored. Success of the
mRNA mpox vaccine in early animal trials shows promise. The
U.S Government awarded them $176 million to develop a bird flu vaccine showing their continued support and trust. The positive CHMP opinion for updated
COVID-19 jab boosts faith in its efficiency. Reported side-effects and low EU sales adversely affected Moderna's stock by 20%.
Novavax and mRNA vaccines have been approved and are being compared for differences. Legal issues plague Moderna as investors have the opportunity to lead a securities fraud lawsuit. A proposed mRNA drug hopes to treat a devastating childhood disease. Production for a combined COVID-flu vaccine is underway, and experimental mpox vaccine reportedly reduces severity of the disease. The Food and Drug Administration (FDA) approved Moderna’s mRNA RSV vaccine for older adults, while Moderna’s updated COVID-19 vaccine recently won U.K. approval. Much progress continues, but Moderna’s decision to halt plans for a Kenyan mRNA vaccine plant after a $1B financial hit is worrisome.
Moderna MRNA News Analytics from Mon, 27 Nov 2023 08:00:00 GMT to Sun, 08 Sep 2024 17:05:02 GMT -
Rating 4
- Innovation 6
- Information 8
- Rumor 3
